Physician profile
Asaad Elbashir
NPI 1841558657
$2,370.34
in general payments reported to CMS, 2019-2025
25 companies · $809 in 2025
The $809 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $91.45 · 2021: $60.08 · 2023: $527 · 2024: $579 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,826 · Education: $88.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,825.59 |
| Education | $88.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $390.36 | 2019-2025 | Sogroya, Wegovy |
| Abbvie INC. | $347.58 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $293.07 | 2023-2025 | |
| Dexcom, INC. | $218.09 | 2020-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $193.32 | 2025 | Freestyle Libre 3 |
| Tolmar, INC. | $144.42 | 2023-2025 | Fensolvi |
| Alexion Pharmaceuticals, INC. | $126.62 | 2019-2021 | |
| Kyowa Kirin, INC. | $91.45 | 2023-2024 | Crysvita |
| Beta Bionics, INC. | $60.40 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sobi, INC | $52.01 | 2019 | |
| Tandem Diabetes Care, INC. | $50.23 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ucb, INC. | $46.86 | 2019-2025 | Fintepla |
| Xeris Pharmaceuticals, INC. | $42.65 | 2020-2024 | Gvoke Hypopen |
| Azurity Pharmaceuticals, INC. | $41.61 | 2023-2025 | Triptodur, Triptodur |
| Neurocrine Biosciences, INC. | $41.06 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Soleno Therapeutics, INC. | $33.73 | 2025 | Vykat Xr |
| Lilly USA, LLC | $33.34 | 2019 | |
| Arbor Pharmaceuticals, INC. | $31.06 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $23.42 | 2023 | Imcivree |
| Endo Pharmaceuticals INC. | $21.31 | 2023 | Supprelin |
| Ferring Pharmaceuticals INC. | $21.17 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $19.91 | 2025 | |
| Zogenix INC. | $18.01 | 2021 | |
| Medtronic Minimed, INC. | $15.32 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $13.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asaad Elbashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.